Company Overview
Snapshot
Founded in September 2008 by Eliahu Kaplan, Novaremed operates with 1–10 employees. The company has secured $67.16M in total capital across 6 funding rounds from 3 investors. In July 2022, Novaremed entered into an exclusive option and license agreement with NeuroFront for its non-opioid neuropathic pain treatment, NRD.E1, for Greater China and Singapore.
Business overview
Novaremed is a clinical-stage biopharmaceutical company focused on developing non-opioid treatment options for chronic pain. The company's core product, NRD.E1, is an orally active small molecule with FDA Fast Track Designation, currently in Phase 2b clinical trials for painful diabetic peripheral neuropathy. Novaremed also has earlier-stage candidates, MP-101 and MP-103, targeting chemotherapy-induced peripheral neuropathy. The company aims to address significant medical needs in pain management associated with diabetes and cancer, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In July 2022, Novaremed entered an exclusive option and license agreement with NeuroFront for its lead non-opioid neuropathic pain treatment, NRD.E1, covering Greater China and Singapore. This agreement signals significant market expansion potential and strategic validation for Novaremed's pipeline, indicating investor confidence in the global commercial viability of its drug candidates and a potential acceleration of its market reach in key Asian territories.
Log in to access full profile ›Company Intelligence Q&A
- What is Novaremed's lead product?
- Novaremed's lead product is NRD.E1, an orally active non-opioid small molecule with a novel mechanism of action. It has received FDA Fast Track Designation and IND-approval to proceed with a Phase 2b clinical trial for the treatment of painful diabetic peripheral neuropathy.
- When did Novaremed acquire Metys Pharmaceuticals?
- In September 2021, Novaremed acquired Metys Pharmaceuticals, expanding its pipeline of non-opioid treatment candidates for chronic pain indications.
- Has Novaremed received any FDA designations for its products?
- Yes, in December 2020, Novaremed received Fast Track Designation from the FDA for NRD.E1 for the treatment of painful diabetic peripheral neuropathy.
- What was a key strategic partnership for Novaremed in 2022?
- In July 2022, Novaremed entered into an exclusive option and license agreement with NeuroFront for the non-opioid neuropathic pain treatment, NRD.E1, for Greater China and Singapore.
- When did Novaremed announce the publication of Phase 1 and Phase 2a study data for NRD.E1?
- In June 2022, Novaremed announced the publication of Phase 1 and Phase 2a study data for NRD.E1, demonstrating the potential of this investigational non-opioid pain treatment.